3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
7
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
52
Brain Neoplasms
28
Glioma
22
Gliosarcoma
19
Melanoma
18
Astrocytoma
17
Central Nervous System Neoplasms
11
Oligodendroglioma
10
Neoplasms
9
Neoplasm Metastasis
8
Recurrence
6
Carcinoma, Non-Small-Cell Lung
5
Neuroblastoma
4
Lymphoma
4
Ependymoma
4
Diffuse Intrinsic Pontine Glioma
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Neurologic Manifestations
2
Neuroectodermal Tumors, Primitive
2
Neoplasms, Second Primary
2
Meningeal Carcinomatosis
2
Medulloblastoma
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocytopenia
1
Tetanus
1
Spinal Cord Neoplasms
1
Solid Tumors
1
Small Cell Lung Cancer Recurrent
1
Interventions
etoposide phosphate
1
Transplantation, Homologous
1
Transplantation, Autologous
1
Therapeutics
1
Temozolomide
1
Radiotherapy
1
RRx-001
1
Patient Discharge
1
Microarray Analysis
1
Irinotecan
1
Immunohistochemistry
1
Ifosfamide
1
Dexamethasone
1
Dasatinib
1
Carboplatin
1
Calcium Dobesilate
1
Bone Transplantation
1
Blotting, Western
1
3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Spinal Cord Neoplasms
×
Temozolomide
×
Clear all
NCT04525014
2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1
Terminated
2 enrolled